In plain language
Thymosin alpha-1 is a thymus-derived peptide that helps regulate immune function. Unlike most peptides in this encyclopedia, it is an approved medicine in several countries (marketed as thymalfasin/Zadaxin) for conditions such as hepatitis B, and it has been studied in infections and as a cancer-treatment adjunct. It is not FDA-approved in the United States.
What it is explored for
Thymosin alpha-1 stands on unusually solid ground for a peptide, being an approved medicine in several countries for conditions like hepatitis B. It is valued for the way it helps balance and restore immune function, and it has the most clinical history of many peptides in this encyclopedia.
- Immune system support and modulation
- Balanced T-cell and immune signaling
- Antiviral immune support
- Adjunct interest in cancer care
- Immune and inflammatory balance
- Stronger response to vaccination in older adults
These are areas of active interest and reported use, not proven outcomes. This peptide carries a moderate evidence rating, see the evidence summary below for how strong the science actually is.
How it works
Thymosin alpha-1 modulates immune responses, particularly T-cell function. It has a more developed clinical literature than most research peptides.
- T-cell modulation. Promotes maturation and activity of T cells and supports balanced immune responses.
- Innate immune signaling. Interacts with toll-like receptor pathways to influence dendritic cells and overall immune activation.
- Antiviral and adjunct use. Used clinically in some countries for chronic hepatitis B and studied as an adjunct in other infections and cancers.
Mechanisms are supported by clinical as well as preclinical data, though results vary by condition and not all uses are well established.
Evidence summary
Thymosin alpha-1 has a substantial clinical record, including approval in several countries for hepatitis B and study in sepsis, vaccination response, and cancer support. Evidence quality varies by indication and it is not FDA-approved, placing it at moderate confidence overall, stronger than most peptides here.
Reported safety & side effects
With approved use in several countries, thymosin alpha-1 has a relatively established safety profile and is generally well-tolerated, with injection-site reactions among the more common effects. Use in the US is off-label or via compounding.
Frequently asked
Is thymosin alpha-1 FDA-approved?
Not in the United States. It is approved and marketed in a number of other countries (as thymalfasin/Zadaxin), notably for chronic hepatitis B.
How is it different from the other thymus peptides here?
It has a stronger clinical evidence base and regulatory approval abroad, whereas products like Thymalin and Thymagen rest mostly on older, regional research.